You are here: Industry Insights > IFM

News List

IFM Due signs immunotherapy deal with Novartis pharmaceutical-technology
September 10, 2019
IFM Due, a subsidiary of IFM Therapeutics, has entered a collaboration and exclusive option agreement with Novartis...
Novartis to buy IFM Tre for up to $1.57bn pharmaceutical-technology
April 03, 2019
Novartis has agreed to acquire anti-inflammatory group IFM Tre, a subsidiary of IFM Therapeutics, in a deal worth up to $1.57bn.
Bristol-Myers Squibb completes previously announced acquisition of IFM Therapeutics worldpharmanews
September 08, 2017
Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has completed the previously announced planned acquisition of IFM Therapeutics.
Regen Addresses Potential Impact of Bristol Myers Squibb's $2.3 Billion Acquisition of IFM americanpharmaceuticalreview
August 11, 2017
On August 3, 2017 Bristol Myers Squibb (BMS) announced that it had entered into an agreement to acquire IFM Therapeutics, a smaller biotech company focused on developing therapies that modulate novel targets in the innate immune system to treat cancer, au
Bristol-Myers Squibb to buy IFM Therapeutics for $300m pharmaceutical-technology
August 08, 2017
Bristol-Myers Squibb (BMS) has entered a definitive agreement to purchase all outstanding capital stock of IFM Therapeutics (IFM) for $300m.
Bristol-Myers Squibb’s $2.3 billion gamble to boost cancer pipeline pharmafile
August 07, 2017
Bristol-Myers Squibb has agreed a deal to acquire IFM Therapeutics for a potential $2.3 billion. The latter is a biotech that only last year completed its series A funding, gaining $27 million to back its venture in the process.